Clinical Pharmacokinetic (PK) / Pharmacodynamic (PD) Model for Debio 1143, a Novel Antagonist of IAPs in Cancer Treatment

E Rouits (1), P Olsson Gisleskog (2), B Gavillet (1), M Sorensen (3), C Zanna (1), G Vuagniaux (1), V Nicolas-Métral (1)

Presented at ASCO 2014, Chicago, USA

Debiopharm International SA, Lausanne Switzerland
SGS Exprimo NV, Mechelen, Belgium
Ascenta Therapeutics, Malvern, USA